» Articles » PMID: 19887966

Phase II Trial of Nanoparticle Albumin-bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer

Overview
Journal J Thorac Oncol
Publisher Elsevier
Date 2009 Nov 6
PMID 19887966
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Carboplatin/paclitaxel chemotherapy with bevacizumab is an accepted standard treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). The development of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) has circumvented many of the infusion difficulties associated with standard solvent-based paclitaxel (in Cremophor) and offers theoretical advantages in efficacy. This trial evaluated the combination of nab-paclitaxel, carboplatin, and bevacizumab in advanced (stage IIIB/IV) nonsquamous NSCLC.

Methods: Fifty patients with stage IIIB/IV NSCLC were enrolled between October 2005 and April 2006; 48 were treated with nab-paclitaxel 300 mg/m2, carboplatin area under the curve = 6, and bevacizumab 15 mg/kg every 21 days until progression or intolerable toxicity, up to 4 cycles; an additional 2 cycles could be administered to responding patients and the physician's discretion; maintenance bevacizumab was not administered. Patient demographics included: 56% female, median age 67 years (range, 32-83), performance status 0 (52%) or 1 (48%), adenocarcinoma 86%, and stage IV disease 82%. Responding patients received a minimum of 4 cycles. The primary end point was response rate.

Results: Response rate was 31% with a stable disease rate of 54%. No complete responses were observed. Median progression-free survival was 9.8 months (range, <1-22.3), and median survival was 16.8 months. Most frequent grades 3 and 4 treatment-related toxicities were neutropenia (54%) and fatigue (17%).

Conclusions: The combination of nab-paclitaxel, carboplatin, and bevacizumab was well tolerated with moderate neutropenia. Adverse events were manageable. Survival results are encouraging. These results indicate that this combination has promising activity as first-line therapy in patients with nonsquamous NSCLC.

Citing Articles

Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426.

Ichikawa Y, Seki N, Honda T, Sakugawa M, Hosokawa S, Bessho A Transl Cancer Res. 2023; 12(4):873-886.

PMID: 37180670 PMC: 10175006. DOI: 10.21037/tcr-22-2144.


A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer.

Zhang Y, Wang Z, Shen L, Li J, Huang J, Su W Cancer Commun (Lond). 2022; 43(1):150-153.

PMID: 36331272 PMC: 9859731. DOI: 10.1002/cac2.12379.


Preparation and Characterization of Chitosan and Inclusive Compound-Layered Gold Nanocarrier to Improve the Antiproliferation Effect of Tamoxifen Citrate in Colorectal Adenocarcinoma (Caco-2) and Breast Cancer (MCF-7) Cells.

Kahlous Y, Palanirajan V, Starlin M, Negi J, Cheah S Turk J Pharm Sci. 2022; 19(4):391-399.

PMID: 36047535 PMC: 9438755. DOI: 10.4274/tjps.galenos.2021.48961.


Temperature and pH Dual Responsive Nanogels of Modified Sodium Alginate and NIPAM for Berberine Loading and Release.

Chang S, Qin D, Yan R, Zhang M, Sui B, Xu H ACS Omega. 2021; 6(2):1119-1128.

PMID: 33490771 PMC: 7818125. DOI: 10.1021/acsomega.0c03965.


A phase II study of concurrent nab-paclitaxel/carboplatin combined with thoracic radiotherapy in locally advanced squamous cell lung cancer.

Wu K, Zhu L, Wang J, Pan K, Wang B, Li X J Thorac Dis. 2020; 11(11):4529-4537.

PMID: 31903241 PMC: 6940262. DOI: 10.21037/jtd.2019.10.81.